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Introduction
Fibrosis results from excessive extracellular matrix deposition that accompanies chronic inflammation or 
wound healing and is a key pathogenic process in many organs, including the liver. Liver fibrosis is a conse-
quence of  chronic liver injury associated with alcoholic or nonalcoholic fatty liver disease, viral hepatitis, or 
metabolic diseases (1). Although the pathogenesis of  fibrosis has common features across different organs, 
the exact mechanisms involved are not fully understood. Unfortunately, there is no effective antifibrotic ther-
apy approved for human use; therefore, there is an urgent need for identifying novel treatment modalities.
For multifactorial chronic diseases, such as fibrosis, the conventional pharmacological approach based 
on the “one-disease/one-target/one-drug” paradigm limits therapeutic efficacy and could be improved by 
simultaneously hitting multiple therapeutic targets (2). Although this could be achieved by combination 
therapy, there are drawbacks to using multiple chemical entities, such as differences in pharmacokinetics 
and target organ engagement, and a wider range of  drug-drug interactions and adverse effects. These issues 
could be mitigated by developing a single drug that has more than one therapeutic target. When applied 
to liver fibrosis, such an approach could aim at both preventing its progression and reversing the process, 
leading to improved liver function (3). This could best be achieved by engaging targets involved not only in 
Liver fibrosis, a consequence of chronic liver injury and a way station to cirrhosis and 
hepatocellular carcinoma, lacks effective treatment. Endocannabinoids acting via cannabinoid-1 
receptors (CB1R) induce profibrotic gene expression and promote pathologies that predispose to 
liver fibrosis. CB1R antagonists produce opposite effects, but their therapeutic development was 
halted due to neuropsychiatric side effects. Inducible nitric oxide synthase (iNOS) also promotes 
liver fibrosis and its underlying pathologies, but iNOS inhibitors tested to date showed limited 
therapeutic efficacy in inflammatory diseases. Here, we introduce a peripherally restricted, orally 
bioavailable CB1R antagonist, which accumulates in liver to release an iNOS inhibitory leaving 
group. In mouse models of fibrosis induced by CCl4 or bile duct ligation, the hybrid CB1R/iNOS 
antagonist surpassed the antifibrotic efficacy of the CB1R antagonist rimonabant or the iNOS 
inhibitor 1400W, without inducing anxiety-like behaviors or CB1R occupancy in the CNS. The 
hybrid inhibitor also targeted CB1R-independent, iNOS-mediated profibrotic pathways, including 
increased PDGF, Nlrp3/Asc3, and integrin αvβ6 signaling, as judged by its ability to inhibit these 
pathways in cnr1–/– but not in nos2–/– mice. Additionally, it was able to slow fibrosis progression 
and to attenuate established fibrosis. Thus, dual-target peripheral CB1R/iNOS antagonists have 
therapeutic potential in liver fibrosis.
Downloaded from http://insight.jci.org on February 19, 2018.   https://doi.org/10.1172/jci.insight.87336
2insight.jci.org   doi:10.1172/jci.insight.87336
R E S E A R C H  A R T I C L E
the fibrotic process itself, but also in the underlying pathologic conditions that predispose to liver fibrosis, 
as described above.
One such target is the endocannabinoid/cannabinoid-1 receptor (endocannabinoid/CB1R) system. 
Endocannabinoids are lipid signaling molecules that act on the same cannabinoid receptors — CB1 and 
CB2 — that mediate the effects of  marijuana (4). An overactive endocannabinoid/CB1R system contrib-
utes to visceral obesity and its complications (5), including type 2 diabetes (6), and also plays a role in 
the pathology of  alcoholic fatty liver disease (7) and viral hepatitis (8). Conversely, CB1R blockade has 
beneficial effects in preclinical models of  these conditions (7, 9) as well as in overweight individuals with 
metabolic syndrome (10). Endocannabinoids acting via CB1R have also been implicated in liver fibrosis 
in the absence of  obesity, and the prototype CB1R inverse agonist rimonabant has moderate antifibrotic 
efficacy in animal models (11). However, rimonabant and related brain-penetrant CB1R antagonists cause 
psychiatric side effects due to blockade of  CB1R in the CNS, which halted their therapeutic development. 
Non-brain-penetrant CB1R antagonists have recently been reported to retain the metabolic benefit of  glob-
ally acting compounds (6, 12, 13), but their therapeutic potential in liver fibrosis has not yet been evaluated.
Another potential therapeutic target involved in both fibrosis and its underlying pathologies is inducible 
nitric oxide synthase (iNOS), an enzyme that catalyzes the generation of  proinflammatory reactive nitro-
gen species. iNOS-producing hepatic macrophages have been identified as the main fibrogenic cell popula-
tion in experimental liver fibrosis (14), which can be attenuated by genetic deletion (15) or pharmacologic 
inhibition of  iNOS (16). Furthermore, increased iNOS activity contributes to alcoholic liver disease (17) 
and the progression of  viral hepatitis (18) and is also involved in diet-induced steatohepatitis (19), insulin 
resistance (20), and obesity-associated inflammation and endoplasmic reticulum dysfunction (21). Thus, 
iNOS is another promising therapeutic target for liver fibrosis. However, first-generation iNOS inhibitors 
lacked oral bioavailability (16), whereas more recently developed, orally bioavailable iNOS inhibitors have 
had disappointingly low therapeutic efficacy in clinical trials involving inflammatory diseases (22).
Here, we introduce a peripherally restricted CB1R inverse agonist, which accumulates in the liver to 
release a metabolically cleaved leaving group with potent iNOS inhibitory activity, resulting in high expo-
Figure 1. Chemical structure and CB1R affinity and selectivity of a hybrid CB1R/iNOS inhibitor. (A) Design and chemical structure of the CB1R-active enantio-
mer (-)-MRI-1867. (B) CB1R-binding affinity and CB1R/CB2R selectivity of (-)-MRI-1867. Binding affinity was determined by computer-assisted analysis of binding 
displacement isotherms using 1 nM or 0.6 nM of [3H]-CP55940 as the labeled ligand and plasma membranes from CB1R- or CB2R-expressing CHO-K1 cells, 
respectively. Ki values were calculated using the Cheng-Prusoff equation. Data represent mean ± SEM from 3 independent experiments performed in triplicates.
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sure of  both targets in the liver without detectable exposure of  CB1R in the brain. In two mouse models of  
liver fibrosis, the antifibrotic efficacy of  the hybrid compound exceeds that of  rimonabant due to inhibition 
of  profibrotic pathways uniquely engaged by iNOS, as verified through the use of  mice deficient either in 
CB1R or iNOS, and is able not only to slow fibrosis progression, but also to attenuate established fibrosis.
Figure 2. Peripheral selectivity of MRI-1867. (A) Tissue distribution of MRI-1867, as determined by LC-MS/MS 1 hour after acute or 28-day chronic oral dos-
ing at 3 and 30 mg/kg. Numbers below graphs indicate concentrations in nM of unbound MRI-1867 in brain, determined by equilibrium dialysis using brain 
membranes from CB1R
–/– mice. (B) Brain CB1R occupancy by MRI-1867 or rimonabant, as determined by CB1R PET following acute or chronic treatment with 
the indicated doses. Data in A and B represent mean ± SEM from 3–4 mice/group. Data from the same 3 vehicle-treated mice were used as controls for 
both the acute and chronic pretreatment groups, and the same representative CB1R PET image from a vehicle-treated mouse is shown for both the acute 
and chronic pretreatment groups. (C) Rimonabant (3 mg/kg), but not MRI-1867 (3-30 mg/kg), is anxiogenic in the elevated plus maze test (n = 6 [vehicle], 
n = 5 [rimonabant], and n = 6 [MRI-1867] mice/group). Data in B and C were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test,  
*P < 0.05 relative to vehicle.
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Results
Design and pharmacological properties of  a dual CB1R/iNOS inhibitor. In order to optimize the antifibrotic ther-
apeutic potential of  CB1R blockade, we have modified the structure of  the brain-penetrant CB1R antago-
nist/inverse agonist ibipinabant (23) to generate compounds with limited brain penetrance while retaining 
high potency and selectivity as CB1R antagonist and also acting as parent drug or pro-drug to directly 
inhibit iNOS activity.
The design of  peripherally restricted hybrid CB1R/iNOS inhibitors involved chemically attaching an 
acetamidine moiety, known for its iNOS inhibitory activity (24), to the core chemical scaffold (see the 
Methods, Figure 1, and Supplemental Figures 1 and 2; supplemental material available online with this 
article; doi:10.1172/jci.insight.87336DS1). Acetamidine is a polar chemical moiety with limited ability 
to penetrate biological membranes, so its chemical attachment to the apolar sulfonylurea scaffold would 
increase the polar surface area of  the hybrid structure, limiting its brain penetrance. Furthermore, the 
hybrid compound could serve as a pro-drug and a carrier for the iNOS inhibitory moiety, facilitating the 
Figure 3. Inhibition of iNOS by a hybrid CB1R/iNOS antagonist. (A) Metabolism of MRI-1867 by liver microsomes yields acetamidine and a urea 
metabolite. (B) Effects of MRI-1867, acetamidine, rimonabant, and positive control diphenylene iodonium (DPI, iNOS inhibitor, 1 mM) on iNOS activity 
in RAW 264.7 cells preincubated with LPS (50 ng/ml) plus γ-interferon (10 ng/ml) for 24 hours. (C) Lack of effect of MRI-1867, rimonabant, or acet-
amidine on eNOS activity, determined by using recombinant eNOS enzyme. L-NNA (Nω–nitro-L-arginine, 100 μM) was used as positive control. Data 
in B and C were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test, *P < 0.05 indicates significant inhibition of iNOS relative 
to LPS- or LPS+γ-interferon–treated control.
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delivery of  the latter into hepatocytes and resulting in high target exposure. The chemical structure of  
the lead compound (-)-MRI-1867, from here on referred to as MRI-1867, and its physicochemical and 
pharmacological properties are illustrated in Figure 1. The absolute configuration of  MRI-1867 was 4S, as 
indicated by the X-ray diffraction data (Supplemental Figure 3B). The low brain penetrance of  MRI-1867 
is reflected in its very low (~3%) brain/plasma Cmax ratio after either acute or 28-day chronic oral admin-
istration of  the maximally efficacious dose of  3 mg/kg, with no significant accumulation in the brain 
evident after chronic dosing (Figure 2A). Of  note, the compound accumulated highly in the liver (Figure 
2A), yet displayed no hepatotoxicity, as reflected by normal plasma levels of  alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST) following 28-day chronic administration of  oral doses of  3 
or 30 mg/kg (ALT: 28.5 ± 1.3 U/l, 31.8 ± 4.8 U/l, and 26.2 ± 3.4 U/l; AST: 39.7 ± 5.4 U/l, 44.0 ± 6.1 
U/l, and 36.2 ± 1.2 U/l in control, 3, and 30 mg/kg drug groups, respectively). The low brain penetrance 
of  MRI-1867 could be partly attributed to its increased polar surface area relative to rimonabant and 
ibipinabant (Table 1) but also to its being a substrate of  p-glycoprotein-mediated reverse transport at the 
blood-brain barrier. This is suggested by an efflux ratio of  2.5 in a Caco-2 permeability assay (Supplemen-
tal Table 1) and further confirmed by the marked increase in its brain penetrance and brain CB1R occupan-
cy, associated with a central CB1R-mediated behavioral effect in mdr1α
–/– mice (Supplemental Figure 4).
In the brain, 98.6% of  MRI-1867 is nonspecifically protein bound, as determined by equilibrium dial-
ysis using brain membranes from CBr1–/– mice. The brain concentration of  unbound drug following acute 
or chronic oral dosing with 3 mg/kg was 0.2–0.3 nM, which is well below its IC50 of  40 nM in a functional 
(GTPγS) assay and its binding affinity for CB1R (Ki: 2.3 nM, Figure 1B and Table 1). Even after treatment 
Figure 4. Effects of rimonabant or MRI-1867 on progression of biliary fibrosis. Wild-type, cnr1–/–, and nos2–/– mice received daily oral doses of 3 mg/kg of 
either compound for 2 weeks, starting on the day of bile duct ligation (BDL). (A) Liver fibrosis determined histologically by Sirius red staining; fibrosis area 
analyzed by computerized morphometry or (B) by hydroxyproline content. Scale bar: 100 μm. Data represent mean ± SEM from 6 (nos2–/–) or 9 mice/group (wt, 
cnr1–/–). Data in A and B were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test. Significant difference from corresponding values in 
sham-operated controls (*P < 0.05), from values in vehicle-treated BDL group (#P < 0.05), or between rimonabant and MRI-1867-treated groups (+P < 0.05).
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with a 10 times higher dose, unbound drug concentrations in the brain (0.9–1.2 nM) remained below the Ki 
for CB1R (Figure 2A). As a result, acute or chronic treatment of  mice with 3–30 mg/kg MRI-1867 failed to 
cause significant displacement of  a CB1R PET ligand (25) in in vivo PET imaging studies, whereas 3 mg/kg 
rimonabant caused significant, marked displacement (Figure 2B). Accordingly, MRI-1867 at doses up to 30 
mg/kg did not induce anxiety-like behavior in the elevated plus maze, an effect triggered by CB1R blockade 
in the CNS, whereas rimonabant caused pronounced anxiety at 3 mg/kg (Figure 2C).
The inverse agonist properties of  MRI-1867 were documented both in vitro using the GTPγS binding 
assay and in vivo using a functional assay to quantify CB1R-mediated changes in upper gastrointestinal 
motility (26). In the absence of  an agonist, MRI-1867 caused concen-
tration-dependent decreases in GTPγS binding, and at oral doses of  
3–10 mg/kg, it significantly increased upper GI motility in control but 
not in CBr1–/– mice, both effects indicating inverse agonism at CB1R 
(Supplemental Figure 5, A and C). The same assays were used to 
assess competitive antagonism of  CB1R by MRI-1867, which concen-
tration-dependently inhibited GTPγS binding stimulated by 300 nM 
of  the CB1R agonist, CP-55,940, and also dose-dependently reversed 
the inhibition of  upper GI motility caused by a 10 mg/kg dose of  the 
CB1R agonist, arachidonoyl 2-chloroethylamide, with rimonabant 
causing similar inhibition in the same dose or concentration range 
(Supplemental Figure 5, B and D). So, in subsequent experiments, a 
daily oral dose of  3 mg/kg was used for both compounds.
The acetamidine metabolite and the cleaved chemical scaffold 
were both detectable by LC-MS/MS in the supernatant of  mouse liver 
microsomes incubated with 3 μM MRI-1867, indicating that acetami-
dine is generated by hepatic metabolism of MRI-1867 (Figure 3A). 
These two metabolites could also be detected in peripheral blood plas-
ma 1 hour after oral administration of  MRI-1867 (data not shown). 
Both MRI-1867 and its leaving group acetamidine caused concen-
tration-dependent inhibition of  iNOS activity in the 1–10 μM range 
when tested in vitro in cell-free extracts of  RAW 264.7 mouse mac-
rophages treated with LPS + γ-interferon to induce iNOS expression 
Table 1. Physicochemical and pharmacodynamic properties of MRI-1867
(-)-MRI-1867 Rimonabant Ibipinabant
cLogP 6.1 6.01 6.16
tPSA 100.5 50.16 74
Mouse Rat Human Mouse Mouse
Ki CB1R (nM) 2.3 ± 0.4 8.0 ± 2.0 1.2 ± 0.6 4.5 ± 1.0 8.1 ± 1.2
EC50, CB1R-induced [
35S]GTPγS (nM) 40 ± 7 N.D. N.D. 25 ± 5 76 ± 7
Plasma protein binding (%) 99.6 99.88 99.86 N.D. N.D.
Protein binding in CB1R
–/– brain (%) 98.6 N/A N/A N.D. N.D.
tPSA, total Polar Surface Area; N.D., not determined.
 
Figure 5. Effects of rimonabant and MRI-1867 on gene expression of fibro-
sis markers. Wild-type, cnr1–/–, and nos2–/– mice received daily oral doses of 
3 mg/kg/d of either compound for 2 weeks, starting on the day of bile duct 
ligation (BDL). Gene expression of collagen 1a (col1a), transforming growth 
factor-β1 (tgfβ1), α-smooth muscle actin (acta2), and tissue inhibitor of 
metalloproteinase-1 (timp1) was assayed by real-time PCR. Data repre-
sent mean ± SEM from 6 (nos2–/–) or 9 mice/group (wt, cnr1–/–). Data were 
analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test. 
Significant difference from corresponding values in sham-operated controls 
(*P < 0.05) or from values in vehicle-treated BDL group (#P < 0.05).
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(Figure 3B). Note that the inhibitory concentrations are below the peak hepatic concentration of  unmetabo-
lized MRI-1867 following its acute or chronic administration at a therapeutically efficacious dose (Figure 2A). 
In contrast, rimonabant at up to 100 μM did not inhibit iNOS. Finally, the inhibitory effects were selective for 
iNOS, as endothelial NOS (eNOS) activity was unaffected by MRI-1867 or acetamidine (Figure 3C).
Druggable properties of  MRI-1867. The oral bioavailability of  MRI-1867 was 81%, defined as the ratio 
of  AUC following oral gavage versus intravenous administration of  a 3 mg/kg dose in Sprague-Dawley 
Figure 6. Attenuation of hepatic iNOS activity and protein levels in biliary fibrosis by MRI-1867 but not rimonabant. (A) Immunostaining for iNOS protein 
in wild-type, cnr1–/–, or nos2–/– mice. Scale bar: 50 μm. (B) nos2 mRNA in wild-type or cnr1–/– mice. (C) Hepatic iNOS enzyme activity, as measured by the 
conversion of arginine to citrulline (see Methods). (D) Hepatic 3-nitrotyrosine levels. (E) Effects of MRI-1867 on hepatic CB1R mRNA and endocannabinoid 
levels in bile duct ligation (BDL) mice. (F) Effect of treatments on serum ALT and AST in wild-type mice with BDL. Mean ± SEM from 9 (wt), 9 (cnr1–/–), or 6 mice 
(nos2–/–) are shown. Data were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test. Significant difference from corresponding values 
in sham-operated controls (*P < 0.05), from values in vehicle-treated BDL group (#P < 0.05), or between rimonabant and MRI-1867-treated groups (+P < 0.05).
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Figure 7. CB1R-independent profibrotic pathways targeted by  
MRI-1867. Effects of MRI-1867 and rimonabant on (A) pdgfb/p-
dgfbr/cd248, (B) αVβ6, and (C) asc3/nlrp3 pathways in wild-type, 
cnr1–/–, and nos2–/– mice with bile duct ligation (BDL). Note that MRI-
1867 but not rimonabant reverses BDL-induced increases in gene 
expression and (D) Nlrp3 protein levels, and its inhibitory effect is 
retained in cnr1–/– but lost in nos2–/– mice. Scale bar: 100 μm. Mean 
± SEM from 6 mice/group. Data were analyzed by 1-way ANOVA 
followed by Dunnett’s multiple comparisons test. Significant 
difference from corresponding values in sham-operated controls 
(*P < 0.05), from values in vehicle-treated BDL group (#P < 0.05), or 
between rimonabant and MRI-1867-treated groups (+P < 0.05).
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rats. Plasma t1/2 was ~4 hours for orally administered MRI-1867 in both mice and rats. Microsomal sta-
bility assays, using mouse, rat, or human liver microsomal preparations indicated that 46%–62% of  the 
compound remained unmetabolized following 1 hour of  incubation at 37°C (Supplemental Table 2). A 
2-strain Ames test for in vitro genotoxicity was negative at a dose of  up to 125 μg/ml MRI-1867 (Supple-
mental Table 3). In an in vitro assay, the IC50 of  MRI-1867 for inhibition of  the K
+ current mediated by 
hERG (human ether-à-go-go-related gene) was 5.1 μM (Supplemental Table 4). One μM MRI-1867 was 
also tested in a safety screen, including selected receptors, ion channels, and enzymes (Cerep), and the 
only positive hit other than CB1R (93% displacement) was for the κ opioid receptor (61% displacement, 
Supplemental Table 5). However, in a functional screen testing for agonist as well as antagonist activity, 
the same concentration of  MRI-1867 did not interact with the κ opioid receptor or with any of  a series 
of  192 GPCRs other than CB1R (Supplemental Table 6). Finally, MRI-1867 has >500-fold selectivity for 
CB1R over CB2R (Figure 1B).
Antifibrotic activity of  MRI-1867 in bile duct ligation–induced liver fibrosis. We compared the antifibrot-
ic effects of  rimonabant and MRI-1867 in two murine models of  liver fibrosis with different etiologies, 
induced either by bile duct ligation (BDL) or carbon tetrachloride (CCl4) treatment.  
BDL is an experimental model featuring biliary fibrosis and cirrhosis with periportal hepatocyte death 
(27). The BDL model is relevant to clinical entities such as extrahepatic biliary atresia and primary scle-
rosing cholangitis, in which the liver injury is associated with interruption of  bile flow to the gut. In this 
model, the irreversible nature of  liver injury enables one to determine its drug-induced regression. There-
fore, we have used two different treatment paradigms. To assess the prevention of  fibrosis, treatments 
Figure 8. Differential effects of rimonabant and MRI-1867 on macrophage infiltration in the fibrotic liver. (A) CD68+ macrophages (scale bar: 100 μm) 
and tunel-positive apoptotic cells (scale bar: 50 μm) in the liver; effects of bile duct ligation (BDL) and chronic treatment of BDL mice with rimonabant or 
MRI-1867. (B) Ccl2 gene expression in the livers of the same animals. Mean ± SEM from n = 8 (wt), n = 8 (BDL + V), n = 7 (BDL + rimo), and n = 7 (BDL + MRI). 
Data were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test. Significant difference from corresponding values in sham-operated 
controls (*P < 0.05), from values in vehicle-treated BDL group (#P < 0.05), or between rimonabant and MRI-1867-treated groups (+P < 0.05).
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started immediately after fibrogenesis initiation by BDL surgery. As for mitigating established fibrosis, in 
preliminary studies we determined that marked fibrosis was evident within 6 days of  the ligation of  the 
common bile duct, and it showed very low intersubject variability, so attenuation of  fibrosis was tested by 
starting drug treatments on day 6 after BDL. The potential role of  the secondary target iNOS in the antifi-
brotic activity of  MRI-1867 was assessed in two ways: first, by comparing its antifibrotic efficacy with that 
of  an equipotent CB1R inhibitory dose of  rimonabant, and second, by testing its effects in CB1R knockout 
(cnr1–/–) as well as iNOS knockout (nos2–/–) mice with BDL-induced fibrosis.
MRI-1867 was significantly more efficacious than rimonabant, both dosed at 3 mg/kg/d, in preventing 
the progression of  BDL-induced collagen deposition in the liver, as quantified histologically by Sirius red 
staining (Figure 4A) and biochemically by measuring hydroxyproline (Hyp) content (Figure 4B). BDL also 
induced marked ductular proliferation, which was again attenuated significantly more effectively by MRI-
1867 than by rimonabant (Supplemental Figure 6). Compared with wild-type mice, BDL-induced fibrosis 
was less pronounced in both cnr1–/– and nos2–/– mice. In cnr1–/– mice, it could be further attenuated by MRI-
1867 but not by rimonabant, whereas in nos2–/– mice, the 2 compounds had similar antifibrotic efficacy 
(Figure 4A). In wild-type mice with BDL, both compounds significantly reduced the gene expression of  the 
fibrosis markers collagen-1, Tgfβ1, α-smooth muscle actin (αSma), and tissue inhibitor of  metalloprotease-1 
(Timp1), with MRI-1867 being significantly more effective than rimonabant. Its effects were retained in 
cnr1–/– mice (Figure 5).
BDL induced a robust increase in iNOS expression in the liver. This was documented by iNOS immu-
nostaining evident in hepatocytes (Figure 6A) as well as iNOS gene expression (Figure 6B); both were 
completely prevented by MRI-1867 in both wild-type and cnr1–/– mice, whereas rimonabant did not affect 
iNOS protein levels and only partially reduced iNOS gene expression. These findings were in accordance 
with the similar increase in BDL-induced iNOS expression in the wild-type and Cnr1–/– liver (Figure 6, A 
and B). The specificity of  iNOS immunostaining was indicated by its absence in nos2–/– mice (Figure 6A). 
MRI-1867 also completely prevented the BDL-induced increase in iNOS function, as quantified by hepatic 
iNOS enzyme activity (Figure 6C) or hepatic protein nitrosylation (Figure 6D), with rimonabant having no 
significant effect in either assay. BDL also increased cnr1 expression and hepatic endocannabinoid levels, 
and these changes were reversed by MRI-1867 treatment (Figure 6E). These effects are likely due to CB1R 
Figure 9. Effect of rimonabant, MRI-1867, and iNOS inhibitor 1400W on regression of biliary fibrosis. Wild-type mice with bile duct ligation (BDL) were 
sacrificed at day 6 after BDL or treated with daily oral doses of vehicle, 3 mg/kg/d of rimonabant or MRI-1867, or 10 mg/kg/d of 1400W starting on day 6 
after BDL to assess fibrosis regression. (A) Liver fibrosis was analyzed by Sirius red staining and quantified by morphometry and by (B) hydroxyproline con-
tent. Scale bar: 100 μm. Data represent mean ± SEM, n = 5 (control), n = 5 (BDL + V), 8 (BDL + rimo), n = 8 (BDL + 1867), and n = 8 (BDL + 1400W) mice/group. 
Data were analyzed by 1-way ANOVA followed by Dunnett’s multiple comparisons test. Significant difference from corresponding values in sham-operated 
controls (*P < 0.05), from values in vehicle-treated BDL group (#P < 0.05), or between rimonabant and MRI-1867-treated groups (+P < 0.05).
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blockade, as judged by similar effects reported with rimonabant (28). CB1R blockade also appears to be 
responsible for the attenuation of  the elevated plasma AST and AST levels by both antagonists (Figure 6F).
The antifibrotic activity of  MRI-1867 in CB1R
–/– mice suggests that in addition to sharing some targets 
with CB1R, iNOS can also uniquely target fibrotic processes not affected by CB1R. The criteria used to 
identify such targets in mice with BDL-induced fibrosis included the inhibition of  their increased gene 
expression in wild-type mice by MRI-1867 but not by rimonabant and the inhibitory effect of  MRI-1867 
remaining unchanged in cnr1–/– mice but being absent in nos2–/– mice. As illustrated in Figure 7, we have 
identified multiple fibrogenic targets that meet these criteria: the PDGF/PDGFRβ system (29) and its 
Figure 10. Antifibrotic effect of MRI-1867 in hepatocellular fibrosis. Wild-type mice were treated with CCl4  
(1 ml/kg i.p., diluted 1:10 in corn oil) twice weekly and were concomitantly treated with vehicle, rimonabant (3 mg/
kg), or MRI-1867 (3 mg/kg) daily for 4 weeks. (A) Fibrosis, as assessed by Sirius Red staining and hydroxyproline 
content. Scale bar: 100 μm. (B) Fibrogenic gene expression. (C) Differential effect of MRI-1867 and rimonabant 
on CCl4-induced increased iNOS protein expression in liver. Scale bar: 50 μm. Data represent mean ± SEM, n = 5 
(control), n = 6 (CCl4+V), n = 6 (CCl4 + Rim), and n = 6 (CCl4+1867) mice/group. Data were analyzed by 1-way ANOVA 
followed by Dunnett’s multiple comparisons test. *P < 0.05 indicates significant difference from control; #P < 
0.05 indicates significant treatment effect relative to CCl4-treated vehicle group; 
+P < 0.05. (+P < 0.05) indicates 
significant difference between rimonabant and MRI-1867-treated groups. 
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downstream mediator CD248 (endosialin) (30), which promote the differentiation of  quiescent stellate 
cells into profibrotic myofibroblasts (Figure 7A); αvβ6 integrin, which is expressed in activated epithelial 
cells and is a marker of  the progression of  biliary and portal fibrosis as well as an activator of  latent TGF-β 
(31) (Figure 7B); and the Nlrp3 inflammasome and its associate protein Asc3, which play a prominent role 
in liver inflammation associated with drug- or obesity-related liver fibrosis (32) (Figure 7C). Unique activa-
tion of  these pathways by iNOS but not by CB1R may contribute to the differential antifibrotic efficacy of  
MRI-1867 and rimonabant.
BDL was associated with marked infiltration of  the liver by CD68+ macrophages (Figure 8A), probably 
driven by the elevated levels of  the chemokine Ccl2 (Figure 8B) and causing hepatocellular damage, as 
indicated by the parallel increase in apoptotic cells (Figure 8A). Macrophage infiltration and hepatocyte 
apoptosis as well as the elevated levels of  Ccl2 were more effectively suppressed by MRI-1867 than by 
rimonabant, and MRI-1867 remained effective in cnr1–/– but not in nos2–/– mice (Figure 8B). Furthermore, 
MRI-1867 but not rimonabant was able to completely arrest the progression, with a tendency to reverse 
BDL-induced liver fibrosis when treatment was started on day 6 after BDL (Figure 9). Daily treatment with 
a near-maximal inhibitory dose of  10 mg/kg of  the iNOS inhibitor 1400W attenuated fibrosis to the same 
extent as rimonabant but was less effective than MRI-1867. BDL-induced fibrosis involved marked bridg-
ing, which remained evident in rimonabant- or 1400W-treated treated mice but was practically abolished/
prevented by MRI-1867 in both treatment paradigms (Figure 4A and Figure 9).
Antifibrotic activity of  MRI-1867 in CCl4-induced liver fibrosis. CCl4-induced fibrosis is widely used as a 
chemically induced liver fibrosis model, which features centrilobular hepatocyte death (27). As fibrosis 
induced by short-term (<8 weeks) CCl4 remains reversible, this model is suitable to determine drug-induced 
prevention but not reversal of  fibrosis. Mice were treated twice weekly for 4 weeks with 1 ml/kg CCl4 to 
induce liver fibrosis (27) and simultaneously treated with vehicle, MRI-1867 (3 mg/kg/d), or rimonabant 
(3 mg/kg/d). Fibrosis was attenuated significantly more by MRI-1867 than by rimonabant, as documented 
histologically by Sirius red staining (Figure 10A), by the reduced hepatic Hyp content, fibrogenic gene 
expression (Figure 10B), and iNOS protein expression (Figure 10C).
Finally, we tested MRI-1867 for attenuating obesity and its metabolic consequences, known predispos-
ing factors for liver fibrosis, based on the documented effectiveness of  other peripherally restricted CB1R 
antagonists in mouse models of  obesity (12, 33). In C57BL6/J mice with high-fat diet-induced obesity, 
chronic treatment with MRI-1867 caused dose-dependent reductions in body weight, hepatic steatosis, and 
improved glucose tolerance (Supplemental Figure 7).
Discussion
We have introduced a type of  peripherally restricted hybrid compound that simultaneously acts on two 
targets previously associated with the development and progression of  liver fibrosis of  different etiolo-
gies, CB1R and iNOS. Using MRI-1867, a potent, orally bioavailable, non-brain-penetrant CB1R inverse 
agonist with additional activity as a direct inhibitor of  iNOS, we demonstrate that the engagement of  the 
secondary target results in a CB1R-independent increase in antifibrotic efficacy relative to the efficacy of  
the single-target CB1R antagonist rimonabant in mouse models of  both hepatocellular and biliary fibrosis.
The hybrid compound has unique pharmacokinetic as well as pharmacodynamic features. As for phar-
macokinetics, its limited access to CB1R in the brain minimizes its ability to elicit behavioral effects pre-
dictive of  neuropsychiatric side effects in humans, thus avoiding the pitfall that plagued first-generation, 
brain-penetrant CB1R antagonists. The lack of  detectable occupancy of  CB1R in the brain at doses up to 10 
times the efficacy dose was demonstrated in real time by CB1R PET, which indicates a favorable therapeutic 
index regarding centrally mediated adverse effects. Features that limit the brain penetrance of  the hybrid 
compound include an increase in its polar surface area as well as its being a substrate of  the P-glycopro-
tein-mediated reverse transport through the blood-brain barrier, the latter indicated by its increased brain 
penetrance in mdr1α-deficient mice.
Furthermore, by incorporating the iNOS inhibitory polar acetamidine moiety into the apolar core 
chemical scaffold, one could overcome the lack of  oral bioavailability of  acetamidine, yielding very high 
target organ exposure through the hepatic uptake and accumulation of  the parent compound or “pro-drug,” 
from which the acetamidine moiety is released through metabolic cleavage. Of  note, the very high hepatic 
concentration of  the hybrid inhibitor is not associated with hepatotoxicity, as reflected by unchanged plas-
ma ALT and AST levels in mice chronically treated with MRI-1867.
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Regarding the pharmacodynamics of  the hybrid CB1R/iNOS inhibitor, two important principles 
have emerged from efforts to develop effective antifibrotic therapies. First, antifibrotic treatment strategies 
could aim to control the primary disease, to inhibit fibrogenic gene expression and signaling, to promote 
molecular mechanisms involved in fibrosis regression, or a combination of  these (1). Second, with mul-
tiple molecular mechanisms and signaling pathways involved in fibrosis, targeting more than one could 
increase antifibrotic efficacy (34), and the hybrid CB1R/iNOS inhibitor embodies optimal characteristics 
on both accounts.
As to the first principle, both the endocannabinoid/CB1R system and iNOS are ideal targets, as they are 
known to be involved directly in the fibrotic process and also in the conditions predisposing to liver fibrosis, 
as detailed in the Introduction. An emerging major predisposing factor to liver fibrosis is nonalcoholic fatty 
liver disease (35), and CB1R blockade has proven effective in mitigating obesity-related hepatic steatosis in 
both rodent models (36) and humans (37). The other two major predisposing factors, alcoholic fatty liver 
disease and viral hepatitis, also involve increased CB1R activity. Hepatic CB1R expression is induced either 
by chronic ethanol intake (7) or the hepatitis C virus (38), and CB1R blockade mitigates alcohol-induced 
steatosis (7) and inhibits hepatitis C virus production (39). The demonstrated ability of  MRI-1867 to atten-
uate diet-induced obesity and its metabolic consequences may also contribute to its efficacy in mitigating 
liver fibrosis when obesity is a contributing factor. Furthermore, CB1R blockade has therapeutic potential 
not only in conditions that predispose to fibrosis, but also in hepatocellular carcinoma (40), which has been 
epidemiologically linked to progressive liver fibrosis (41, 42).
In addition to mitigating predisposing factors, CB1R blockade can also directly engage profibrotic gene 
expression and signaling in the liver, inhibition of  which has been shown to contribute to the therapeu-
tic efficacy of  CB1R blockade (11, 43–46), cnr1 gene deletion (47), or RNAi-mediated cnr1 knockdown 
(48) in models of  liver fibrosis without underlying obesity. Furthermore, CB1R antagonism increases the 
expression of  matrix metalloprotease-1 (49) involved in extracellular matrix degradation and decreases 
the expression of  its inhibitor TIMP1 (43) and could thus promote fibrosis reversal. Here, we have shown 
that peripheral CB1R blockade by MRI-1867 can engage all three of  the above mechanisms, most likely by 
reversing the fibrosis-related increase in hepatic endocannabinoid “tone,” which is reflected in the increased 
hepatic CB1R expression as well as hepatic endocannabinoid levels in the fibrotic liver (Figure 6E).
As for the secondary target iNOS, its activation as a proinflammatory mechanism contributing to fibro-
sis progression has been well documented, as detailed in the Introduction. In addition, iNOS protein and 
enzyme activity are markedly elevated in the livers of  patients with cirrhosis caused by viral hepatitis, alco-
hol abuse, and cholestasis (50). There are also reports supporting an opposite, antifibrotic role of  NO and 
iNOS in liver fibrosis induced by thioacetamide (51) or prolonged high-fat diet (52). However, other findings 
indicate that NO involved in fibrosis resolution and the related improvement in hepatic circulation may be 
generated via eNOS, which, in contrast to iNOS, is downregulated in fibrosis (53, 54). The present obser-
vations are in agreement with the majority of  findings supporting the profibrotic function of  iNOS (53–56) 
and the antifibrotic effect of  iNOS inhibition (56, 57). This is evident in the markedly reduced levels of  
BDL-induced fibrosis in the livers of  nos2–/– mice (Figure 4), which are also known to be less sensitive to 
CCl4-induced cirrhosis compared with wild-type mice (15). The antifibrotic efficacy of  the iNOS inhibitor 
1400W in BDL-induced fibrosis (Figure 8) further supports the profibrotic function of  iNOS. The contribu-
tion of  iNOS inhibition to the antifibrotic efficacy of  MRI-1867 is clearly indicated by its antifibrotic activity 
in cnr1–/– mice and by the loss of  its differential efficacy relative to rimonabant in nos2–/– mice (Figure 4).
The greater antifibrotic efficacy of  MRI-1867 compared with rimonabant suggests that iNOS inhibition 
selectively blunts profibrotic signaling in the liver that is unaffected by CB1R blockade. Unique iNOS targets 
have been defined as being inhibited by MRI-1867 in wild-type and cnr1–/– mice but not in nos2–/– mice. One 
such target is the PDGF/PDGFRβ pathway and its downstream mediator endosialin (CD248), which pro-
mote the proliferation and transdifferentiation of  quiescent stellate cells into profibrotic myofibroblasts (58). 
MRI-1867 may inhibit this pathway by blocking iNOS-mediated NO production in hepatocytes, thus pre-
venting a possible paracrine effect of  NO on neighboring stellate cells. Activation of  TGF-β, the other major 
growth factor pathway involved in stellate cell activation is suppressed by CB1R blockade, but iNOS inhibi-
tion also targets TGF-β via blocking the expression of  αvβ6 integrin, a cell adhesion molecule expressed in 
proliferating bile duct epithelial cells that binds latent TGF-β to release active TGF-β (31, 59). αvβ6 Integrin 
is also expressed in hepatic progenitor cells, in which it promotes their differentiation into cholangiocytes 
and hepatocytes, whereas inactivation of  αvβ6 promotes hepatic fibrosis and cholangiopathy models (60). 
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Thus, iNOS inhibition may mitigate fibrosis not only via antiinflammatory mechanisms, but also by inhib-
iting the regenerative capacity of  the liver. On the other hand, the greater antifibrotic activity of  MRI-1867 
compared with 1400W (Figure 8) may reflect mechanisms uniquely targeted by CB1R blockade, such as the 
increased tissue levels of  anandamide and the increased expression of  CB1R in the fibrotic liver.
CB1R is expressed by multiple cell types in the liver, including hepatocytes (61), stellate cells (11), and 
infiltrating macrophages (6), and iNOS is also known to be expressed in hepatocytes (50) as well as hepatic 
macrophages (14). Further studies are needed to explore the relative contribution of  different types of  liver 
cells as targets of  the antifibrotic effect of  combined inhibition of  CB1R and iNOS.
Interestingly, in wild-type mice with either BDL-induced or CCl4-induced liver fibrosis, rimonabant 
moderately reduced iNOS gene and protein expression (Figure 5 and Figure 8). An explanation of  
this may involve recent findings that fibrosis progression is driven by the infiltration of  the liver with 
proinflammatory macrophages expressing the Nlrp3 inflammasome (62) and that activation of  CB1R on 
such macrophages promotes their transmigration and proinflammatory activity, whereas CB1R block-
ade produces opposite effects (6) and also suppresses the expression of  NF-κB (63), a transcription fac-
tor promoting nos2 gene expression (64). In contrast to rimonabant, MRI-1867 completely reversed the 
increase in iNOS activity, most likely due to the enzyme inhibitory action of  the acetamidine leaving 
group. The parallel inhibition of  nos2 gene expression is similar to findings with other iNOS inhibitors 
(57) and likely reflects the blockade of  a positive feedback loop, whereby peroxynitrite generated via 
iNOS leads to the upregulation of  NF-κB and, consequently, nos2. Thus, inhibition of  iNOS by the 
acetamidine leaving group may well contribute to the exceptionally high antifibrotic efficacy of  the 
dual-target CB1R/iNOS inhibitor.
The dual targeting of  peripheral CB1R and iNOS demonstrated here exemplifies the therapeutic gain 
obtained by simultaneously hitting more than one molecule, which could then engage distinct as well as 
convergent cellular pathways. The advantage of  such an approach is highlighted by emerging experience 
with recently developed antifibrotic medications, which indicates that targeting a single pathway has lim-
ited effect on fibrotic diseases (34). Thus, the approach illustrated by the present study has promise as an 
effective antifibrotic strategy.
Methods
Additional details are provided in the Supplemental Methods .
Chemistry. The chemical synthesis, purification and verification of  the structure of  MRI-1867 are 
described in the Supplemental Methods.
Materials. Rimonabant and CP-55,940 were obtained from the National Institute of  Drug Abuse Drug 
Supply Program (Research Triangle Park, North Carolina, USA). Arachidonoyl-2′-chloroethylamine 
(ACEA) and Fumonisin B were from Cayman. [2H4]AEA was synthesized by the reaction of  arachidonoyl 
chloride with [2H4]ethanolamine (65). [
3H]CP55,940, [35S]GTPγS, [3H]arginine, and [14C(U)]arginine were 
from Perkin-Elmer. All other chemicals were from Sigma-Aldrich.
Animals. Male 8- to 10-week-old C57BL/6J mice were obtained from The Jackson Laboratory. Mice 
were maintained under a 12-hour-light/12-hour-dark cycle and fed ad libitum. To induce liver fibrosis, 
10- to 12-week-old mice were subjected either to BDL surgery or CCl4 treatment as indicated. To generate 
diet-induced obesity, C57BL/6J mice were fed a high-fat diet (D12492, Research Diets Inc., 60% of  calo-
ries as fat). Lean controls were mice kept on a standard laboratory diet (NIH-31 rodent diet) for 14 weeks. 
Cnr1–/– mice were generated as described previously (66). Nos2–/– mice were purchased from The Jackson 
Laboratory. Cnr1–/–, nos2–/–, and mdr1a–/– mice were on C57Bl/6J genetic background.
Induction of  liver fibrosis by CCl4. Hepatocellular liver fibrosis was generated by i.p. injection of  CCl4 (1 
ml/kg, diluted 1:10 corn oil) twice weekly. Animals were sacrificed 40 hour after the last CCl4 dose.
Induction of  liver fibrosis by BDL. Ligation of  the common bile duct was performed as described previ-
ously (67). Average survival was 18–20 days after the surgery. Therefore the study was completed at 14 days 
after surgery, at which time severe fibrosis was evident with low interindividual variability.
Drug treatment. The compounds were administered by oral gavage daily in both acute and chronic stud-
ies as indicated.
Blood chemistry. Blood was collected at the time the mice were sacrificed. Serum ALT and AST were 
quantified using AMS Vegasys Chemistry Analyzer (Diamond Diagnostics). Blood glucose was deter-
mined using the Elite glucometer (Bayer).
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Hepatic triglyceride content. Liver tissue was extracted as described previously (33), and its triglyceride 
content was determined using the EnzyChrom Triglyceride Assay kit (BioAssay Systems).
Glucose tolerance and insulin sensitivity tests. The assays were performed (13) following 1 week of  daily 
oral doses of  MRI-1867, as described. i.p. glucose tolerance tests were performed after overnight fasting by 
i.p. administration of  glucose at 1.5 mg/kg and subsequent sampling of  tail blood at 15-minute intervals. 
i.p. insulin sensitivity tests were performed on the next day after a 6-hour fast by treating mice with a bolus 
dose of  insulin (0.75 U/kg). Blood glucose levels were measured from tail blood.
CB1R-binding assays. The assay was performed as described previously (68). Briefly, binding affinity of  
the compounds to CB1R and CB2R was determined by radioligand displacement assays using 1 and 0.6 
nM of  [3H]CP55,940 as the radioligand, respectively. Plasma membranes were prepared from mouse and 
rat brain or from cultured CHO-K1 cells stably transfected with human CB1R or CB2R (Perkin Elmer). 
Twenty microgram or four microgram plasma membrane protein was used in a 1-ml reaction mixture for 
rodent and human sources, respectively. Ki values were derived by computerized curve fitting and using 
the Cheng-Prusoff  equation to account for the affinity of  the radioligand, using the GraphPad Prism 6 
program (GraphPad Prism Software Inc.).
[35S]GTPγS-binding assay. The assay was performed as described previously (68). Inverse agonism by 
MRI-1867 and rimonabant was determined in the absence of  agonist, whereas their potency as antagonists 
(IC50) was determined in the presence of  the agonist CP55,940 (300 nM), which generated a CB1R-medi-
ated increase in GTPγS binding at the ~EC80 level. Ten μg plasma membrane protein was used in a 1.0-ml 
reaction mixture.
Upper GI motility assay. The assay was performed as described previously (68). To determine inverse 
agonism, MRI-1867 or rimonabant was administered orally by gavage to male 8- to 10-week-old mice 1 
hour prior to an oral bolus of  10% charcoal suspension in 5% gum arabic. Thirty minutes later, the mice 
were killed, and the distance traveled by the head of  the marker between the pylorus and the cecum was 
measured and expressed as percentage of  total length of  the small intestine. To assess in vivo CB1R antago-
nism, MRI-1867 or rimonabant was administered 30 minutes after an oral dose of  the CB1R agonist ACEA 
(5 mg/kg), with the rest of  the procedure as described above.
Hyperambulatory activity. The assay was performed as described previously (68). Locomotor activity of  
drug-naive mice treated with an oral bolus dose of  a CB1R antagonist or vehicle was quantified by the num-
ber of  disruptions of  infrared beams in 2 dimensions in an activity chamber. The drugs were administered 
3 hour after the start of  the light cycle.
Elevated plus-maze test. Anxiety-related behavior was assessed using the elevated plus-maze test as 
described previously (33). Mice were tested 1 hour after either acute or 28-day chronic oral administration 
of  rimonabant or MRI-1867.
Real-time PCR analyses. RNA extraction was performed using RNeasy Mini Kits (Qiagen). One 
microgram of  total RNA was reverse transcribed to cDNA using SuperScript II (Invitrogen). Expression 
of  the target gene was quantified with gene-specific primers and PowerSYBR Green master mix (ABI) 
using a 7500 Real-Time PCR instrument (Applied Biosystems). Predesigned mouse Rpl19, tgfb1, acta2, 
timp1, nos2, and cnr1 primers were purchased from Qiagen. Gene expression values were calculated based 
on the ΔΔCt method.
PET. In vivo CNS CB1R occupancy by MRI-1867 and rimonabant was assessed by their ability to dis-
place the CB1R PET radiotracer [
18F]FMPEP-d2, as described previously (12). The specific activity of  the 
PET radiotracer at the time of  injection was 927 ± 212 mCi/μmol (mean ± SD). Lean control mice (26 ± 
3 g) were treated orally with MRI-1867 (3, 10, and 30 mg/kg), rimonabant (3 mg/kg), or vehicle 1 hour 
prior to radioligand injection. Concurrent to injection of  127 ± 29 μCi of  [18F]FMPEP-d2, PET scans began 
and continued for 120 minutes on a Siemens microPET Focus 120 camera (Siemens Medical Solutions). 
Images were reconstructed without attenuation and scatter correction. For each animal, a brain time activity 
curve was constructed and activity was expressed as a standardized uptake value, which compensates for the 
injected activity and body weight. Whole brain uptake was determined by area under the time activity curve 
from 60 to 120 minutes after radioligand injection.
Endocannabinoid measurements. The tissue levels of  endocannabinoids were measured by stable isotope 
dilution liquid chromatography/tandem mass spectrometry (LC-MS/MS) as described previously (69).
Nonspecific protein binding in brain. Nonspecific binding of  MRI-1867 to brain tissue was determined by 
equilibrium dialysis as described previously (12) using crude brain membrane preparations from CB1R
–/– 
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mice. The membranes were incubated with 2 μM MRI-1867 in D-tube dialyzer maxi dialysis apparatus 
(Novagen). The levels of  free (unbound) MRI-1867 were determined by LC-MS/MS.
Tissue levels of  drugs. Tissues and plasma were extracted as described previously (69), and MRI-1867 
levels were determined by LC-MS/MS using an Agilent 6410 triple quadrupole mass spectrometer (Agilent 
Technologies) coupled to an Agilent 1200 LC system (Agilent Technologies). Chromatographic and mass 
spectrometer conditions were set as described previously (70). Levels of  each compound were analyzed 
by multiple reactions monitoring. The molecular ion and fragments for each compound were measured as 
follows: m/z 548.1→145 and 548.1→257.1 for MRI-1867 (CID energy: 56 V and 24 V, respectively), m/z 
59.1→42.1 and 59.1→44.1 for acetamidine (CID energy: 1 V and 2 V, respectively), and m/z 524→105 and 
524→506.3 for a hydroxylated urea metabolite (CID energy: 16 V and 0 V, respectively). The amounts of  
MRI-1867 in the samples were determined against standard curves. Values are expressed as ng/g or ng/ml 
in wet tissue weight or plasma volume, respectively.
Metabolism of  MRI-1867 by liver microsomes. MRI-1867 (3 μM ) was incubated with mouse liver micro-
somes (GIBCO, ThermoFisher Scientific, 2 mg protein/aliquot) at 37°C for 90 minutes in 200 μl reaction 
buffer (100 mM KH2PO4, 4 mM NADPH, 3 mM MgCl2, pH 7.4). Controls containing no MRI-1867 were 
used to establish baseline ion chromatogram. The reaction was stopped by addition of  200 μl of  ice-cold 
methanol and incubation for at least 20 minutes at –20°C. The samples were centrifuged at 13,000 g for 10 
minutes, and the supernatants were analyzed by LC-MS/MS to detect acetamidine.
Fluorimetric iNOS assay. Fluorimetric Cell-Associated Nitric Oxide Synthase Detection System (Sig-
ma-Aldrich) was used for measuring iNOS activity in RAW 264.7 cells (ATCC) as per the supplier’s instruc-
tions. Cells were preincubated with LPS (50 ng/ml) and γ-interferon (10 ng/ml) for 24 hours to induce iNOS 
activity before adding the test compounds for an additional hour, with 100,000 cells/well used per reaction.
Radioisotopic hepatic iNOS activity assay. Hepatic iNOS activity was measured by the rate of  conversion 
of  [14C(U)]L-arginine to [14C(U)]L-citrulline by using a NOS activity assay kit (Cayman). The assay was 
performed as previously described (50) with modifications to yield specific iNOS activity. Briefly, liver sam-
ples (25 mg wet weight) were homogenized by Precellys homogenizer in 5× volume of  ice-cold homogeni-
zation buffer containing 50 mM Tris HCL, 320 mM sucrose, 1 mM DTT, and protease inhibitors (AEBSF 
1 mM, aprotinin 0.8 μM, bestatin 50 μM, E-64 15 μM, leupeptin 20 μM, pepstatin A 15 μM), followed by 
centrifugation at 10,000 g for 20 minutes at 4°C. The supernatant was centrifuged at 100,000 g for 1 hour 
at 4°C to purify the iNOS-containing soluble compartment. Five μl of  the supernatant was incubated at 
37°C for 3 minutes in assay buffer with supplementation of  L-arginine (20 μM), L-citrulline (1 mM), nor-
valine (10 mM), and fumonisin B (300 μM). In the liver, L-arginine and L-citrulline are utilized by urea 
cycle enzymes and are also substrates for arginase and argininosuccinate synthase, respectively. In order to 
prevent the breakdown of  [14C(U)]L-arginine and [14C(U)]L-citrulline by urea cycle enzymes and arginase, 
the argininosuccinate synthase inhibitor fumonisin B and the arginase inhibitor norvaline were added to 
the reaction mixture. The specificity of  the iNOS activity measured was further confirmed by its inhibition 
by 1 mM N-nitro-L-arginine (L-NNA). Enzyme activity was expressed as percentage conversion of  [14C]
L-arginine to [14C]L-citrulline.
Radioisotopic eNOS activity assay. eNOS activities were measured by the rate of  conversion of  [3H]
L-arginine to [3H]L-citrulline by using a NOS activity assay kit (Cayman), as per the supplier’s instruc-
tions. This assay was used to measure the effects of  the test substances on eNOS activity, using recombi-
nant bovine eNOS (Cayman).
3-Nitrotyrosine tissue levels. 3-Nitrotyrosine levels in liver tissue, as an indicator of  protein nitrosylation 
by iNOS, were determined using an ELISA kit from MyBiosource.com (MBS005184).
Hyp measurement by LC-MS/MS. For this method, 50 mg liver tissue was homogenized in 500 μl of  
ice-cold 0.1 N perchloric acid (PCA) to which 500 μl 12 N HCL was added and the homogenate was 
hydrolyzed at 100oC for 4 hours. Hydrolyzed samples were vortexed and centrifuged at 10,000 g for 10 
minutes, and 10 μl hydrolysate was diluted 20-fold by the addition of  190 μl of  0.1 N PCA. LC-MS/ 
MS analyses were conducted on an Agilent 6410 triple quadrupole mass spectrometer (Agilent Tech-
nologies) coupled to an Agilent 1200 LC system. 4-Hyp was separated using an Intrada Amino Acid 
column, 50 × 3 mm, 3 μm (Imtakt) at 40°C. Mobile phases consisted of  acetonitrile/tetrahydrofu-
ran/25 mM ammonium formate/formic acid = 9:75:16:0.3 (v/v/v/v) (phase A) and acetonitrile/100 
mM ammonium formate = 20:80 (v/v) (phase B). Gradient elution (600 μl/min) was initiated and held 
at 0% B for 3 minutes, followed by a linear increase to 17% B by 6.5 minutes. This was followed by a 
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step increase to 100% B, which was held until 10 minutes after the gradient was begun, and then by a 
linear decrease to 0% B by 11 minutes, which was held until 13 minutes after the gradient was begun. 
The mass spectrometer was set for electrospray ionization operated in positive ion mode. The source 
parameters were as follows: capillary voltage, 4,000 V; gas temperature, 330°C; and drying gas, 8 l/min. 
Nitrogen was used as the nebulizing gas. Collision-induced dissociation (CID) was conducted using 
nitrogen. Hyp level was analyzed by multiple reaction monitoring. The molecular ion and fragments for 
Hyp were measured as follows: m/z 132.1→86 and 132.1→68 (CID energy: 8 V and 20 V, respectively). 
Hepatic levels of  Hyp were determined against a standard curve, using trans-4-hydroxy-L-proline as 
standard (Sigma-Aldrich). Values are expressed as nmol/mg wet tissue.
Picrosirius red staining. To visualize fibrotic areas, liver tissue was fixed in 10 % neutralized formalin 
solution and embedded in paraffin. Tissues were cut at 4-μm thickness for staining, and staining was per-
formed as described previously (67).
Tunel staining. Tunel staining was performed using the TUNEL Apoptosis Detection Kit (Millipore 
Corp.). Sections were then counterstained with hematoxylin, Gill’s formula (Vector Labs), and analyzed 
using an Olympus BX41 microscope.
Histology and immunohistochemistry. Liver tissues were fixed in 10 % neutralized formalin solution, 
embedded in paraffin, and sectioned (4μm) onto glass slides. Section were stained with antibody against 
iNOS (Abcam 15323), NLRP3 (Novus Biochemical, NBP2-12446), and CD68 (Abcam 31630) and devel-
oped using ABC-elite-HRP/diaminobenzidine system (Vector Labs), counterstained with hematoxylin, 
Gills Formula (Vector Labs), and analyzed using an Olympus BX41 microscope.
Histology data analysis. Images were taken from at least 8 randomly selected areas from of  each liver sec-
tion. Collagen deposition in liver tissues was quantified by measuring Sirius red–stained areas using ImageJ 
software (NIH) by a person blind to the sample ID. Quantification of  images from one sample was averaged 
for actual data presentation for each sample (n = 6–12 animals/group).
Histological assessment of  ductular proliferation. The degree of  ductular proliferation was assessed in 
H&E–stained sections. The number of  ductular profiles was counted in 50 portal areas from each liver, and 
their average number per portal area was determined.
Statistics. Values shown are expressed as mean ± SEM. Statistical analysis was performed by unpaired 
2-tailed Student’s t test or by 1-way ANOVA, as appropriate. P < 0.05 was considered significant.
Study approval. Animal experiments and protocols were approved by the Institutional Animal Care and 
Use Committee of  the National Institute on Alcohol Abuse and Alcoholism, NIH.
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